AccessibilityHelp

ADARx Pharmaceuticals(NASDAQ) ADRX

Market Cap$1.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-9%
5 YearN/A
1 YearN/A
1 MonthN/A
$17.49
-1.08%
-0.19Today
After hours$17.67+$0.18 (+1.03%)
ADARx Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 17.632026-10-23
ADARx Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.11%USD 17.652026-10-16
Since inception-8.89%USD 19.352026-09-25

ADARx Pharmaceuticals Financials at a Glance

Market Cap

$1.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.09

Net Income (TTM)

-$82.07

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.72 (Low)

Price

$17.49

Volume

177,567.622

Open

$17.68

Previous Close

$17.63

Daily Range

$17.00 - $18.33

52-Week Range

$16.61 - $23.21

Estimated Earnings Date

N/A

ADRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company focused on developing next-generation small interfering RNA (siRNA) therapeutics. The company aims to address significant unmet medical needs in various diseases. Founded in December 2019 and headquartered in San Diego, CA, ADARx is positioned to make a substantial impact in the biotechnology sector.

Products and Services
  • Development of innovative siRNA therapeutics
  • Focus on diseases with significant unmet medical needs
  • Late-stage clinical trials for advanced therapeutic solutions
Growth Outlook
  • Strong pipeline of siRNA therapeutics in late-stage development
  • Potential for significant market share in biotechnology
  • Strategic partnerships to enhance research and development capabilities
Financial Highlights
  • Market capitalization of approximately $2.1 billion
  • Stock price range between $18.5 and $23.21 over the past year
  • Average trading volume of over 2.7 million shares
ADARx Pharmaceuticals is positioned in a promising sector with a focus on innovative therapies that could transform treatment options for patients. The company's commitment to addressing unmet medical needs through advanced siRNA technology highlights its potential for growth. With a solid market capitalization and a robust trading volume, ADARx demonstrates investor interest and confidence in its future prospects. The strategic focus on late-stage clinical trials and partnerships further enhances its potential for success in the competitive biotechnology landscape.
AI Generated • Sep 29, 2026

Industry

Biotechnology

Sector

Health Care

Employees

100

CEO

Zhen Li, PhD

Website

www.adarx.com

Headquarters

San Diego, CA 92121, US

ADRX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$1.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

110.83M

Volume

177.57K

Avg. Volume

758.87K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

ADARx Pharmaceuticals Performance Analysis

ADARx Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 3,449,000N/A
ADARx Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.43N/A
20252025-12-31USD -0.6857.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.75

N/A

Gross Profit

$0.01

N/A

Gross Margin

1.47%

N/A

Market Cap

$1.95BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

100

N/A

Net Income

-$25.76

N/A

EBITDA

-$29.16

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$65.38

N/A

Total Debt

$6.90

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$5.19

N/A

Short Term Debt

$1.71

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$27.56

N/A

Operating Cash Flow

-$27.19

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
STOKStoke Therapeutics, Inc.
$25.04-2.57%
SLNSilence Therapeutics plc
$19.67+0.05%
MGTXMeiraGTx Holdings plc
$9.21-5.73%
PRMEPrime Medicine, Inc.
$3.67-1.61%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.49+1.89%
TAT&T
$20.93-7.96%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$83.56+1.77%
NUNu Holdings
$15.16+2.92%

Questions About ADRX

What is the current price of ADARx Pharmaceuticals?

ADARx Pharmaceuticals is trading at $17.63 per share.

What is the 52-week range for ADARx Pharmaceuticals?

Over the past 52 weeks, ADARx Pharmaceuticals has traded between $16.61 and $23.21.

How much debt does ADARx Pharmaceuticals have?

As of the most recent reporting period, ADARx Pharmaceuticals reported total debt of $6.90M.

How much cash does ADARx Pharmaceuticals have on hand?

ADARx Pharmaceuticals reported $58.48M in cash and cash equivalents in its most recent financial results.

What is ADARx Pharmaceuticals’s dividend yield?

ADARx Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services